A gain of function by the cancer-associated FGFR4 c. 1162G>A (p. Gly388Arg) variant

被引：0
|
作者：
Ulaganathan, V. K. [1 ]
Sperl, B. [1 ]
Mayr, T. [1 ]
Hornberger, R. [1 ]
Rapp, U. R. [2 ]
Ullrich, A. [1 ]
机构：
[1] Max Planck Inst Biochem, Mol Biol, D-82152 Martinsried, Germany
[2] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)50398-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
446
引用
收藏
页码：S107 / S108
页数：2
相关论文
共 25 条
  • [21] FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition
    Ye, Yanwei
    Li, Jie
    Jiang, Dongbao
    Li, Jingjing
    Xiao, Chuangfeng
    Li, Yingze
    Han, Chao
    Zhao, Chunlin
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1162 - 1177
  • [22] Association between FGFR4 Gly388Arg polymorphism rs351855 or the IDH1 rs11554137 and Japanese gastric cancer
    Sera, Tomohiro
    Yashiro, Masakazu
    Yamamoto, Yurie
    Kushitani, Yukako
    Sugimoto, Atsushi
    Kushiyama, Syuhei
    Kuroda, Kenji
    Togano, Shingo
    Okuno, Tomohisa
    Yoshii, Mami
    Tamura, Tatsuro
    Toyokawa, Takahiro
    Tanaka, Hiroaki
    Muguruma, Kazuya
    Ohira, Masaichi
    CANCER RESEARCH, 2020, 80 (16)
  • [23] Association of the fibroblast growth factor receptor-4 (FGFR4) Gly388Arg polymorphism with clinical and pathological response to primary systemic therapy (PST) for early breast cancer (EBC)
    Marme, F.
    Sohn, C.
    Burwinkel, B.
    Sinn, P.
    Hahn, M.
    Lichter, P.
    Benner, A.
    Schneeweiss, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer
    Ziyan Yang
    Jianguo Feng
    Ji Jing
    Yuan Huang
    Wei-Wu Ye
    Lei Lei
    Xiao-Jia Wang
    Wen-Ming Cao
    npj Breast Cancer, 9
  • [25] Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer
    Yang, Ziyan
    Feng, Jianguo
    Jing, Ji
    Huang, Yuan
    Ye, Wei-Wu
    Lei, Lei
    Wang, Xiao-Jia
    Cao, Wen-Ming
    NPJ BREAST CANCER, 2023, 9 (01)
123